Trial Profile
Phase II active comparator study with injectable RT 002 [botulinum toxin A] for the treatment of glabellar lines
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2017
Price :
$35
*
At a glance
- Drugs Daxibotulinumtoxin A (Primary)
- Indications Glabellar lines
- Focus Therapeutic Use
- Acronyms BELMONT
- Sponsors Revance Therapeutics
- 01 Nov 2017 Results published in the Dermatologic Surgery
- 15 Jun 2017 According to a Revance Therapeutics media release, results from this trial published in the Dermatologic Surgery journal.
- 03 Mar 2017 According to a Revance Therapeutics media release, data will be presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting.